Philipp Koehler
Overview
Explore the profile of Philipp Koehler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
3031
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sandherr M, Stemler J, Schalk E, Hattenhauer T, Hentrich M, Hertenstein B, et al.
Lancet Reg Health Eur
. 2025 Feb;
51:101214.
PMID: 39973942
Febrile Neutropenia is an emergency in the treatment of cancer patients. It requires prompt and evidence-based clinical and antimicrobial management. The implementation of standard operating procedures (SOP) across hospitals and...
2.
Cornely O, Sprute R, Bassetti M, Chen S, Groll A, Kurzai O, et al.
Lancet Infect Dis
. 2025 Feb;
PMID: 39956121
Candida species are the predominant cause of fungal infections in patients treated in hospital, contributing substantially to morbidity and mortality. Candidaemia and other forms of invasive candidiasis primarily affect patients...
3.
Hansel L, Cornely O, Koehler P
Clin Microbiol Infect
. 2025 Jan;
PMID: 39864661
No abstract available.
4.
Schmidt A, Casadei N, Brand F, Demidov G, Vojgani E, Abolhassani A, et al.
PLoS Pathog
. 2024 Dec;
20(12):e1012786.
PMID: 39715278
Courses of SARS-CoV-2 infections are highly variable, ranging from asymptomatic to lethal COVID-19. Though research has shown that host genetic factors contribute to this variability, cohort-based joint analyses of variants...
5.
Byrne J, Gu L, Garcia-Leon A, Gaillard C, Saini G, Alalwan D, et al.
Front Immunol
. 2024 Oct;
15:1445653.
PMID: 39355249
Introduction: A clear immune correlate of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has not been defined. We explored antibody, B-cell, and T-cell responses to the third-dose...
6.
Bekaan N, Cornely O, Friede T, Prattes J, Sprute R, Hellmich M, et al.
Clin Microbiol Infect
. 2024 Sep;
31(2):147-151.
PMID: 39251133
No abstract available.
7.
Salmanton-Garcia J, Cornely O, Stemler J, Barac A, Steinmann J, Sivakova A, et al.
J Infect
. 2024 Jul;
89(3):106229.
PMID: 39025408
Introduction: Despite antifungal advancements, candidaemia still has a high mortality rate of up to 40%. The ECMM Candida III study in Europe investigated the changing epidemiology and outcomes of candidaemia...
8.
Stemler J, Yeghiazaryan L, Stephan C, Mohn K, Carcas-Sansuan A, Rodriguez E, et al.
Int J Infect Dis
. 2024 Jul;
146:107161.
PMID: 38992789
Objectives: To assess the safety and immunogenicity of a fourth vaccination (second booster) in individuals aged ≥75 years. Methods: Participants were randomized to BNT162b2 (Comirnaty, 30 µg) or messenger RNA...
9.
Salmanton-Garcia J, Marchesi F, Farina F, Weinbergerova B, Itri F, Davila-Valls J, et al.
EClinicalMedicine
. 2024 Mar;
71:102553.
PMID: 38533127
Background: The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals,...
10.
Bassetti M, Giacobbe D, Agvald-Ohman C, Akova M, Alastruey-Izquierdo A, Arikan-Akdagli S, et al.
Intensive Care Med
. 2024 Mar;
50(4):502-515.
PMID: 38512399
Purpose: The aim of this document was to develop standardized research definitions of invasive fungal diseases (IFD) in non-neutropenic, adult patients without classical host factors for IFD, admitted to intensive...